Carbidopa and levodopa NDC 72888-155

NDC codes

FDA NDC Directory

Product NDC (as listed)72888-155Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72888-0155Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
72888-155-00	72888015500	1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (72888-155-00)Marketed from Jun 4, 2024
72888-155-01	72888015501	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72888-155-01)Marketed from Jun 4, 2024
72888-155-05	72888015505	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (72888-155-05)Marketed from Jun 4, 2024
72888-155-30	72888015530	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (72888-155-30)Marketed from Jun 4, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Carbidopa and levodopa
Generic name (nonproprietary): carbidopa and levodopa
Active ingredients: Carbidopa — 25 mg/1Levodopa — 100 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Advagen Pharma Ltd
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217482
Marketing start: Jun 4, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Aromatic (Chemical structure)
Identifiers: Product ID 72888-155_519a4143-7efb-81ab-e063-6394a90a219bSPL ID 519a4143-7efb-81ab-e063-6394a90a219bSPL set ID 5b6519ff-d1af-402b-83eb-b4fce6743a18RxCUI 308988, 308989UNII 46627O600J, MNX7R8C5VOUPC 0372888156002, 0372888155005, 0372888155050, 0372888156309, 0372888155302, 0372888156019, 0372888156057, 0372888155012
Pharmacologic class: Aromatic Amino Acid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472888015500 followed by a unit qualifier and the quantity

Package 72888-0155-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 12, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217482

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217482
Product	Strength	Form · route	Labeler	Product NDC
Carbidopa and levodopa	Carbidopa 50 mg/1; Levodopa 200 mg/1	Tablet, Extended releaseOral	Advagen Pharma Ltd	72888-156